HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ashfaq Shuaib Selected Research

disufenton sodium (NXY 059)

6/2008NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.
8/2007NXY-059 for the treatment of acute ischemic stroke.
8/2007Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial.
1/2007Neuroprotective effects of free radical scavengers in stroke.
12/2006Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial.
2/2006NXY-059 for acute ischemic stroke.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ashfaq Shuaib Research Topics

Disease

106Stroke (Strokes)
03/2022 - 02/2002
65Ischemic Stroke
03/2022 - 02/2006
24Infarction (Infarctions)
11/2021 - 02/2002
15Ischemia
01/2017 - 02/2002
12Atrial Fibrillation
01/2022 - 03/2003
11Hemorrhage
05/2020 - 02/2002
11Brain Ischemia (Cerebral Ischemia)
09/2008 - 02/2002
9Embolic Stroke
01/2020 - 04/2002
9Hypertension (High Blood Pressure)
10/2019 - 06/2002
9Brain Injuries (Brain Injury)
10/2009 - 04/2002
7Intracranial Hemorrhages (Intracranial Hemorrhage)
05/2020 - 02/2002
7Transient Ischemic Attack
01/2020 - 02/2005
6Vascular Diseases (Vascular Disease)
10/2020 - 07/2003
6Cerebral Hemorrhage
08/2019 - 02/2002
6Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2019 - 07/2003
5Hyperthermia
01/2012 - 03/2005
4Thrombosis (Thrombus)
03/2022 - 01/2003
4Arterial Occlusive Diseases (Arterial Occlusive Disease)
01/2020 - 12/2002
4Traumatic Brain Injuries (Traumatic Brain Injury)
01/2020 - 04/2019
4Cardiovascular Diseases (Cardiovascular Disease)
01/2019 - 11/2010
3Inflammation (Inflammations)
01/2022 - 06/2008
3COVID-19
01/2022 - 01/2020
3Pathologic Constriction (Stenosis)
12/2020 - 06/2015
3Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/2020 - 08/2010
3Diabetes Mellitus
11/2017 - 03/2013
3Acute Coronary Syndrome
10/2013 - 03/2011
3Brain Edema (Cerebral Edema)
04/2005 - 12/2002
3Hypothermia
02/2003 - 04/2002
2Carotid Stenosis (Carotid Artery Stenosis)
12/2020 - 01/2020
2Spinal Cord Injuries (Spinal Cord Injury)
01/2020 - 08/2002
2Infections
01/2020 - 01/2019
2Ganglion Cysts (Ganglion)
08/2019 - 01/2019
2Brain Infarction
03/2016 - 02/2003
2Edema (Dropsy)
07/2015 - 03/2005
2Blood Vessel Dissection
10/2014 - 12/2003
2Headache (Headaches)
10/2014 - 11/2008
2Peripheral Arterial Disease
05/2011 - 03/2011
2Hyperlipidemias (Hyperlipidemia)
11/2005 - 06/2002

Drug/Important Bio-Agent (IBA)

30Tissue Plasminogen Activator (Alteplase)FDA Link
12/2021 - 02/2002
14Neuroprotective AgentsIBA
11/2014 - 02/2002
11AnticoagulantsIBA
03/2022 - 12/2003
10Biomarkers (Surrogate Marker)IBA
03/2022 - 07/2009
9Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
08/2019 - 07/2003
9Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
03/2013 - 07/2003
6salicylhydroxamic acid (SHAM)IBA
08/2019 - 12/2002
6Glucose (Dextrose)FDA LinkGeneric
11/2017 - 01/2007
6disufenton sodium (NXY 059)IBA
06/2008 - 02/2006
5Pharmaceutical PreparationsIBA
01/2018 - 08/2002
5Free RadicalsIBA
06/2008 - 02/2006
4DabigatranFDA Link
05/2020 - 07/2014
4Matrix Metalloproteinases (MMPs)IBA
01/2020 - 07/2006
4LipidsIBA
08/2017 - 06/2002
4Blood Glucose (Blood Sugar)IBA
10/2015 - 06/2008
4Fibrinolytic Agents (Antithrombotic Agents)IBA
10/2013 - 02/2002
4erucylphosphocholineIBA
11/2010 - 01/2005
3Proteins (Proteins, Gene)FDA Link
01/2022 - 05/2011
3Retinaldehyde (Retinal)IBA
01/2022 - 10/2014
3Plasminogen Activators (Plasminogen Activator)IBA
03/2020 - 04/2006
3CholesterolIBA
01/2020 - 04/2010
3RivaroxabanIBA
08/2019 - 01/2016
3CreatinineIBA
08/2019 - 07/2003
3Antihypertensive Agents (Antihypertensives)IBA
01/2019 - 03/2004
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
07/2015 - 09/2008
3Therapeutic UsesIBA
03/2013 - 02/2002
3ZincIBA
03/2013 - 02/2004
3Warfarin (Coumadin)FDA LinkGeneric
05/2011 - 03/2003
2RNA (Ribonucleic Acid)IBA
03/2022 - 01/2021
2omega-Chloroacetophenone (Mace)IBA
01/2022 - 10/2020
2C-Reactive ProteinIBA
12/2021 - 10/2009
2Cytidine Triphosphate (CTP)IBA
01/2020 - 01/2019
2Triglycerides (Triacylglycerol)IBA
01/2020 - 11/2018
2Indicators and Reagents (Reagents)IBA
07/2019 - 04/2014
2Antiviral Agents (Antivirals)IBA
01/2019 - 04/2005
2Desmodus rotundus salivary plasminogen activator alpha 1IBA
12/2016 - 06/2015
2DP-b99IBA
03/2013 - 08/2011
2Chelating AgentsIBA
03/2013 - 08/2011
2Laminin (Merosin)IBA
01/2012 - 05/2011
2Clopidogrel (Plavix)FDA Link
05/2011 - 03/2011
2Proton Pump InhibitorsIBA
05/2011 - 03/2011
2Dipyridamole (Persantine)FDA LinkGeneric
11/2008 - 06/2007
2Simvastatin (Zocor)FDA LinkGeneric
09/2008 - 04/2005
2Coloring Agents (Dyes)IBA
04/2005 - 03/2005
2CytokinesIBA
04/2005 - 06/2002
2Glutamic Acid (Glutamate)FDA Link
04/2005 - 01/2003
2Neurotransmitter Agents (Neurotransmitter)IBA
04/2005 - 01/2003
2N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
04/2005 - 02/2003

Therapy/Procedure

44Therapeutics
01/2022 - 02/2002
8Secondary Prevention
01/2022 - 06/2002
8Thrombolytic Therapy
12/2021 - 03/2005
6Time-to-Treatment
01/2020 - 03/2007
4Thrombectomy
01/2022 - 06/2016
4Lasers (Laser)
01/2021 - 08/2010
4Length of Stay
08/2016 - 12/2015
3Decompressive Craniectomy
01/2020 - 04/2019
2Punctures
01/2020 - 06/2016
2Contraindications
08/2019 - 03/2013
2Coronary Artery Bypass (Coronary Artery Bypass Surgery)
05/2011 - 03/2011
2Percutaneous Coronary Intervention
05/2011 - 03/2011
2Activities of Daily Living (ADL)
04/2009 - 12/2006
2Carotid Endarterectomy
11/2005 - 03/2004